Growing number of people being affected by chronic diseases is likely to be the key driver in the global cloning and mutagenesis market growth. The World Health Organization estimates that by 2020, the prevalence of chronic diseases will rise by 57%. The primary reason for this staggering figure is the increasingly sedentary lifestyle being adopted by people in urban areas. Adding to this are factors such as unhealthy food habits, smoking and drinking, and lack of exercise. As a result, chronic diseases such as obesity and diabetes are on the rise globally. For example, WHO statistics reveal that there were 650 million obese adults (18 years and older) in 2016. These factors will favor the expansion of the global cloning and mutagenesis market size during the forecast period.
Browse Complete Report:
Fortune Business Insights covers some of the major players in the global cloning and mutagenesis market:
- Agilent Technologies, Inc.
- Genomax Technologies Pte Ltd.
- Transgen Biotech Co., LTD
- Thermo Fisher Scientific
- Jena Bioscience GmbH
- New England Biolabs, abm Inc.
- GENEWIZ Inc.
- Takara Bio Inc.
In its report, titled “Cloning & Mutagenesis Market Size, Share and Global Trend By Technique (Blunt End Cloning, Topo PCR Cloning, Seamless Cloning, Site-Directed Mutagenesis), By Product (Cloning Kits, Mutagenesis Kits), By End User (Academic & Research Institutes, Biotechnology Companies) and Geography Forecast till 2026”, Fortune Business Insights has provided a comprehensive analysis of this emerging market. The report also contains a detailed evaluation of the factors, trends, regions, and competition that will influence the development of the global cloning and mutagenesis market till 2026.
Cloning refers to processes by which biological entities such as cells and tissues are genetically replicated either naturally or artificially. Reproductive Cloning, Gene Cloning, and Therapeutic Cloning are the three types of artificial cloning techniques. Mutagenesis, on the other hand, is a technique using which structural and functional relationships between proteins can be studied. It uses the Polymerase Chain Reaction (PCR) method to introduce, substitute, delete, or insert mutations in the DNA.
Increasing Research Activities in Cancer and Other Rare Disorders to Fuel the Market
The global cloning and mutagenesis market is slated for substantial growth owing to the extensive and intensive research being undertaken to develop therapies for cancer and other rare disorders. For example, in 2017, clinical trials were conducted at the Royal Marsden Hospital in London on organoids. These are three-dimensional structures derived from the patient’s cancer cells and are expected to imitate a tumour’s response, representing a cloning technique. This can enable doctors to deliver more targeted and accurate treatment to cancer patients. Similarly, the International Rare Diseases Research Consortium (IRDiRC) has set itself a goal of developing 200 therapies by 2020 for different rare diseases. This bodes well for the global cloning and mutagenesis market revenue as public-funded research are getting a boost from bodies such as the European Commission and the Japan Agency for Medical Research and Development.
Get Sample PDF:
Major Segmental Overview:
- By Technology
- By product
- By End Users
- By Geography
Advancements in Stem Cell Research to Propel the Market in North America
Regionally, North America is anticipated to have a dominant hold on the global cloning and mutagenesis market share in the forecast period. The primary reasons for this being increasing investment in stem cell and cancer research and rising number of biotechnology companies in the region. In Asia-Pacific, a high CAGR is projected on account of increasing prevalence of chronic diseases, evolving healthcare systems, and rising adoption of personalized medication services.
Strategic Collaborations and New Product Launches to Define the Competitive Landscape
In January 2017, Genomax Technologies partnered with Elucigene Diagnostics to bring the latter’s leading prenatal and human genetics diagnostic products to Southeast Asia. Thus, key players in the global cloning and mutagenesis market are entering into strategic partnerships to amplify their market scope. Moreover, novel products are also being launched that are infusing the global cloning and mutagenesis market with new energy. For example, New England Biolabs launched a prep kit for Illumina called NEBNext Single Cell/Low Input RNA Library in 2018.
Speak to Analyst:
View Related reports:
Sleep Apnea Devices Market – Business Revenue, Future Growth, Trends Plans, Top Key Players, Business Opportunities, Industry Share, Global Size Analysis by Forecast to 2026